celecoxib has been researched along with Adenocarcinoma in 96 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 9.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 9.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarcinoma through the induction of apoptosis and the reduction of MVD." | 9.12 | Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. ( Chen, ZX; Huang, MH; Huang, MT; Liu, R; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2007) |
| "Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab." | 7.85 | The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. ( Aranda, E; Cañas, A; Conde, F; de la Haba-Rodríguez, J; Guil-Luna, S; Hernández, V; López-Sánchez, LM; Morales-Estévez, C; Peñarando, J; Rodríguez-Ariza, A; Valverde, A; Villar, C, 2017) |
| " Herein, the effects of the PGHS-2-specific inhibitor celecoxib either alone or in combination with the green tea-derived catechin (-)-epigallocatechin-3-gallate (EGCG) were studied on the expression of interleukin (IL)-1-induced tumorigenic factors in Colo357 human pancreatic adenocarcinoma cells." | 7.78 | (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. ( Falk, W; Härdtner, C; Multhoff, G; Radons, J, 2012) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 7.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 7.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 7.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| " The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats." | 7.75 | Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. ( Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV, 2009) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 7.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| "The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)." | 7.73 | Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 7.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| "Triple negative breast cancers experience the highest pCR rate of 30%." | 6.75 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Celecoxib can enhance apoptosis of GC cell by induction of NAG-1 gene transcription in human." | 6.74 | [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. ( Chen, JP; Ciren, YJ; Tang, CW; Wang, R; Yang, JL; Zhang, B, 2009) |
| "The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation." | 6.73 | Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. ( Auman, JT; Church, R; Fleshman, JW; Lee, SY; Mcleod, HL; Watson, MA, 2008) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 5.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| " Recent studies had shown that the long-term use of high concentration of COX-2 inhibitors is not toxic free and may be limited due to serious gastrointestinal and cardiovascular side effects." | 5.33 | Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. ( Arber, N; Ben-Yosef, R; Figer, A; Kazanov, D; Lev-Ari, S; Starr, A; Yona, D; Zinger, H, 2005) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 5.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 5.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarcinoma through the induction of apoptosis and the reduction of MVD." | 5.12 | Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. ( Chen, ZX; Huang, MH; Huang, MT; Liu, R; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2007) |
| "Single agent gemcitabine (GEM) is the standard treatment of pancreatic adenocarcinoma." | 5.12 | Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L, 2006) |
| " The objective was to evaluate the morphological, hormonal, and inflammatory responses in the prostate anterior lobe in transgenic adenocarcinoma of the mouse prostate (TRAMP), following Celecoxib and Goniothalamin (GTN) treatments." | 3.88 | Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Silva, RS; Vendramini-Costa, DB, 2018) |
| "Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab." | 3.85 | The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. ( Aranda, E; Cañas, A; Conde, F; de la Haba-Rodríguez, J; Guil-Luna, S; Hernández, V; López-Sánchez, LM; Morales-Estévez, C; Peñarando, J; Rodríguez-Ariza, A; Valverde, A; Villar, C, 2017) |
| "The aim of this study was to characterize the structural and molecular biology as well as evaluate the immediate and late responses of prostatic cancer in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model after treatment with goniothalamin (GTN) and celecoxib." | 3.83 | Anti-inflammatory therapies in TRAMP mice: delay in PCa progression. ( Cagnon, VH; Carvalho, JE; Costa, DB; Kido, LA; Macedo, AB; Minatel, E; Montico, F; Pilli, RA; Sauce, R, 2016) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 3.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| " Herein, the effects of the PGHS-2-specific inhibitor celecoxib either alone or in combination with the green tea-derived catechin (-)-epigallocatechin-3-gallate (EGCG) were studied on the expression of interleukin (IL)-1-induced tumorigenic factors in Colo357 human pancreatic adenocarcinoma cells." | 3.78 | (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. ( Falk, W; Härdtner, C; Multhoff, G; Radons, J, 2012) |
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 3.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 3.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| "To see whether celecoxib prevents gastric cancer occurrence by disrupting the progression of chronic gastritis into gastric carcinoma through its inhibition of the migration of CD133-positive cells, one of the surface markers of bone marrow-derived cells, in Helicobacter pylori-infected gerbils." | 3.76 | Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils. ( Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Nagoya, H; Sakamoto, C; Shimpuku, M; Shindo, T, 2010) |
| " We recently showed that NSAIDs such as indomethacin and celecoxib have direct cytotoxicity (ability to induce necrosis and apoptosis in gastric mucosal cells) due to their membrane permeabilizing activities, which is involved in NSAID-induced gastric lesions." | 3.76 | Low direct cytotoxicity of loxoprofen on gastric mucosal cells. ( Arai, Y; Ishihara, T; Kimoto, A; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N; Yokomizo, K, 2010) |
| " In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas." | 3.75 | Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. ( Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL, 2009) |
| " The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats." | 3.75 | Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. ( Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV, 2009) |
| "We created and characterized a mouse mammary adenocarcinoma cell (MMAC-1) line from C3 (1)-SV40 tumor antigen mice to study COX-2 and PPARgamma expression and response to celecoxib and F-L-Leu in vitro." | 3.74 | Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. ( Kruger, WD; Mustafa, A, 2008) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 3.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| "In vivo lung metastases were significantly decreased relative to control by both perioperative and continuous celecoxib (P = ." | 3.73 | Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. ( Backhus, LM; Bart, RD; Bremner, RM; Castanos, R; Lin, GY; Sievers, E; Starnes, VA, 2006) |
| "The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)." | 3.73 | Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006) |
| "To evaluate the effects of neoadjuvant therapy with the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib in vitro and in patients with esophageal adenocarcinoma on COX-2 and MET expression." | 3.73 | Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. ( Buskens, CJ; Kemper, K; Offerhaus, GJ; Richel, DJ; ten Kate, FJ; Tuynman, JB; van Lanschot, JJ, 2005) |
| " In this study, we examined a dose-dependent effect of a cyclooxygenase-2 (COX-2) inhibitor, celecoxib against transgenic adenocarcinoma of the mouse prostate." | 3.73 | Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. ( Narayanan, BA; Narayanan, NK; Pttman, B; Reddy, BS, 2006) |
| "A series of 90 rats underwent a duodenoesophageal reflux surgery were divided into 2 groups: the control group was given a commercial chow and the celecoxib group experimental chow containing celecoxib." | 3.73 | [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats]. ( Fujimura, T; Miwa, K; Oyama, K, 2005) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 3.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| " Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells." | 3.72 | Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. ( Davis, DW; Ellis, LM; Khanbolooki, S; Lashinger, LM; McConkey, DJ; Nawrocki, S; Raut, CP; Xiong, H, 2004) |
| "We found for the first time that (a) both celecoxib and exisulind as dietary supplements induce strong inhibitory effects against prostate cancer at doses of 800 and 500 ppm, respectively, after 16 weeks; (b) the histologic analysis of the dorsolateral prostate after 2 weeks of treatment indicated a reduction of PIN lesions from 75% to 19% with celecoxib and to 16% with exisulind; (c) more importantly, those few PINs and adenocarcinomas in the groups treated with celecoxib or exisulind showed more apoptotic cells, lower levels of proliferating cell nuclear antigen, and a lower number of mitotic cells." | 3.72 | Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. ( Narayanan, BA; Narayanan, NK; Pittman, B; Reddy, BS, 2004) |
| "Celecoxib combined with chemotherapy yields clinical benefits for gastric cancer patients with positive COX-2, which not only enhances the OS, DFS, PFS, QOL, and short-term clinical efficacy, but also does not increase the risk of adverse events." | 2.84 | Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer. ( Chen, Z; Guo, Q; Ji, R; Liu, X; Lu, L; Wang, Y; Yuan, H; Zhou, Y, 2017) |
| "Patients with clinical stage II or III rectal cancer were treated with radiotherapy of 44 Gy in 22 fractions." | 2.79 | Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. ( Chen, HC; Chen, HH; Chen, WT; Chien, CR; Hsiao, CF; Lee, HH; Lin, TC; Lin, TY; Liu, TW; Wang, LW, 2014) |
| "Triple negative breast cancers experience the highest pCR rate of 30%." | 2.75 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Celecoxib can enhance apoptosis of GC cell by induction of NAG-1 gene transcription in human." | 2.74 | [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. ( Chen, JP; Ciren, YJ; Tang, CW; Wang, R; Yang, JL; Zhang, B, 2009) |
| "The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation." | 2.73 | Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. ( Auman, JT; Church, R; Fleshman, JW; Lee, SY; Mcleod, HL; Watson, MA, 2008) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)." | 2.73 | A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007) |
| "Fifty nine gastric cancer patients were randomly divided into 2 groups: celecoxib group (n = 37) and control group (n = 22)." | 2.73 | [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer]. ( Lu, H; Lu, JR; Ran, JT; Tang, CW; Wu, J; Yang, GD; Zhou, YN, 2008) |
| "Serum levels of squamous cell carcinoma antigen and the proliferative potential and subsets of peripheral T cells before and after celecoxib treatment were also analyzed." | 2.71 | Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. ( Battaglia, A; Ferrandina, G; Gessi, M; Lauriola, L; Legge, F; Navarra, P; Ranelletti, FO; Salutari, V; Scambia, G; Testa, AC; Tringali, G; Werner, U, 2003) |
| "The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks." | 2.71 | Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004) |
| "Pancreatic cancer is amongst the most chemoresistant malignancies." | 2.71 | A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. ( Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2005) |
| "Gemcitabine has recently been shown to be an improvement over 5-fluorouracil in patients with advanced disease." | 2.42 | Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. ( Crane, CH; Janjan, NA; Mason, K; Milas, L, 2003) |
| " Herein, we assessed a combination of chidamide plus celecoxib (called CC-01) combined with programmed cell death protein 1 (PD-1) blockade in a CT26 model as potent tumor microenvironment (TME) regulator." | 1.72 | CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. ( Chao, YS; Chen, CN; Chen, JS; Chou, CH; Chu, SH; Wu, YH; Yang, MH, 2022) |
| "DMBA-induced ovarian cancer in rats recapitulates many pathophysiological features of the human counterpart." | 1.48 | Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats. ( Jiang, W; Kang, Y; Shao, Z; Wang, S; Wen, Q; Xu, C; Zhu, T, 2018) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 1.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| " As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2." | 1.40 | Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. ( Girish, GV; Lala, PK; Liu, L; Majumder, M; Xin, X, 2014) |
| "Celecoxib and anti-Gr1 treatment may be useful for blockade of these processes, thereby preventing brain metastasis in patients with breast cancer." | 1.39 | Premetastatic soil and prevention of breast cancer brain metastasis. ( Fellows-Mayle, W; Ikeura, M; Kohanbash, G; Kosaka, A; Liu, Y; Okada, H; Snyder, LA, 2013) |
| "Celecoxib treatment activated Cdc25C and inhibited p21 expression in both unirradiated and irradiated cells, regardless of COX-2 expression." | 1.39 | Different cell cycle modulation by celecoxib at different concentrations. ( Kim, YM; Pyo, H, 2013) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | 1.38 | Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib. ( Marschner, N; Zaiss, M, 2012) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "Celecoxib treatment resulted in a significant reduction in the proliferation of H." | 1.35 | Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. ( Chang, LL; Hu, HM; Jan, CM; Kuo, CH; Tsai, PY; Wang, JY; Wang, WM; Wu, DC; Wu, IC; Yang, SF, 2009) |
| "Treatment with celecoxib alone has no effect on the ERK1/2 activation, Rad51 mRNA and protein levels, however, combined treatment with gefitinib results in a significant reduction of phospho-ERK1/2 and Rad51 protein levels, and triggers the degradation of Rad51 via a 26S proteasome-dependent pathway." | 1.35 | The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. ( Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH, 2009) |
| "Therefore, two clones of a human colon cancer cell line (HT-29) in which GPx2 was stably knocked down by small interfering RNA (siRNA; siGPx2) were used to test whether cancer-relevant processes are affected by GPx2." | 1.35 | Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice. ( Banning, A; Brigelius-Flohé, R; Florian, S; Kipp, A; Krehl, S; Löwinger, M; Schmitmeier, S; Steinberg, P; Thalmann, S; Thierbach, R, 2008) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "The anticancer effects of celecoxib on gastric cancer cells appear to be mediated by cell-cycle arrest and apoptosis, and not by COX-2 or PGE(2) suppression alone." | 1.34 | The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. ( Cho, SJ; Jung, HC; Kim, JS; Kim, N; Song, IS, 2007) |
| "Two human colon cancer cell lines (HCT-15 and HT-29) were treated with 5-FU and celecoxib, alone and in combination." | 1.34 | Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. ( Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC, 2007) |
| "To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy." | 1.34 | [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007) |
| "Lung cancer is the leading cause of cancer deaths in the United States." | 1.34 | Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. ( Crooks, PA; Nakshatri, H; Neelakantan, S; Ralstin, M; Schmidt, CM; Sweeney, CJ; Vegeler, RC; Wu, H; Yip-Schneider, MT, 2007) |
| "Pancreatic neoplasms are associated with a poor prognosis, regardless of treatment modality." | 1.33 | Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel. ( Bartick, T; Chen, S, 2006) |
| " Recent studies had shown that the long-term use of high concentration of COX-2 inhibitors is not toxic free and may be limited due to serious gastrointestinal and cardiovascular side effects." | 1.33 | Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. ( Arber, N; Ben-Yosef, R; Figer, A; Kazanov, D; Lev-Ari, S; Starr, A; Yona, D; Zinger, H, 2005) |
| "Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p." | 1.33 | Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005) |
| "In the present study, we used a pancreatic cancer model to determine the role of Sp1 in the antitumor activity of celecoxib." | 1.32 | Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. ( Abbruzzese, JL; He, Y; Wang, L; Wei, D; Xie, K; Xiong, HQ, 2004) |
| "After establishment of pancreatic cancer, groups 1 and 5 received no therapy, groups 2 and 6 were fed 7 mg Celebrex daily, groups 3 and 7 were given 28 mg Zyflo and groups 4 and 8 received Celebrex and Zyflo orally daily in weeks 17-32." | 1.31 | Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. ( Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 60 (62.50) | 29.6817 |
| 2010's | 35 (36.46) | 24.3611 |
| 2020's | 1 (1.04) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JS | 1 |
| Chou, CH | 1 |
| Wu, YH | 1 |
| Yang, MH | 1 |
| Chu, SH | 1 |
| Chao, YS | 1 |
| Chen, CN | 1 |
| Valverde, A | 1 |
| Peñarando, J | 1 |
| Cañas, A | 1 |
| López-Sánchez, LM | 1 |
| Conde, F | 1 |
| Guil-Luna, S | 1 |
| Hernández, V | 1 |
| Villar, C | 1 |
| Morales-Estévez, C | 1 |
| de la Haba-Rodríguez, J | 1 |
| Aranda, E | 1 |
| Rodríguez-Ariza, A | 1 |
| Guo, Q | 1 |
| Liu, X | 1 |
| Lu, L | 1 |
| Yuan, H | 1 |
| Wang, Y | 2 |
| Chen, Z | 1 |
| Ji, R | 1 |
| Zhou, Y | 1 |
| Silva, RS | 1 |
| Kido, LA | 2 |
| Montico, F | 2 |
| Vendramini-Costa, DB | 1 |
| Pilli, RA | 2 |
| Cagnon, VHA | 1 |
| Wu, C | 2 |
| Li, X | 1 |
| Zhang, D | 1 |
| Xu, B | 1 |
| Hu, W | 1 |
| Zheng, X | 1 |
| Zhu, D | 1 |
| Zhou, Q | 1 |
| Jiang, J | 1 |
| Shao, Z | 1 |
| Wen, Q | 1 |
| Zhu, T | 1 |
| Jiang, W | 1 |
| Kang, Y | 1 |
| Xu, C | 1 |
| Wang, S | 2 |
| Liu, Y | 3 |
| Kosaka, A | 1 |
| Ikeura, M | 1 |
| Kohanbash, G | 1 |
| Fellows-Mayle, W | 1 |
| Snyder, LA | 1 |
| Okada, H | 1 |
| Orlandi, P | 1 |
| Fontana, A | 1 |
| Fioravanti, A | 1 |
| Di Desidero, T | 1 |
| Galli, L | 1 |
| Derosa, L | 1 |
| Canu, B | 1 |
| Marconcini, R | 1 |
| Biasco, E | 1 |
| Solini, A | 1 |
| Francia, G | 1 |
| Danesi, R | 1 |
| Falcone, A | 1 |
| Bocci, G | 1 |
| Raghav, KP | 1 |
| Shetty, AV | 1 |
| Kazmi, SM | 1 |
| Zhang, N | 1 |
| Morris, J | 1 |
| Taggart, M | 1 |
| Fournier, K | 1 |
| Royal, R | 1 |
| Mansfield, P | 1 |
| Eng, C | 1 |
| Wolff, RA | 1 |
| Overman, MJ | 1 |
| Wang, LW | 1 |
| Hsiao, CF | 1 |
| Chen, WT | 1 |
| Lee, HH | 1 |
| Lin, TC | 1 |
| Chen, HC | 1 |
| Chen, HH | 1 |
| Chien, CR | 1 |
| Lin, TY | 1 |
| Liu, TW | 1 |
| Majumder, M | 1 |
| Xin, X | 1 |
| Liu, L | 1 |
| Girish, GV | 1 |
| Lala, PK | 1 |
| Xiang, HG | 1 |
| Xie, X | 2 |
| Hu, FQ | 1 |
| Xiao, HB | 1 |
| Zhang, WJ | 1 |
| Chen, L | 1 |
| Sauce, R | 1 |
| Macedo, AB | 1 |
| Minatel, E | 1 |
| Costa, DB | 1 |
| Carvalho, JE | 1 |
| Cagnon, VH | 1 |
| Li, J | 2 |
| Luo, M | 1 |
| Shang, B | 1 |
| Dong, L | 1 |
| Ilhan, N | 1 |
| Gungor, H | 1 |
| Gul, HF | 1 |
| Eroksuz, H | 1 |
| Auman, JT | 1 |
| Church, R | 1 |
| Lee, SY | 1 |
| Watson, MA | 1 |
| Fleshman, JW | 1 |
| Mcleod, HL | 1 |
| Mustafa, A | 1 |
| Kruger, WD | 1 |
| Falk, GW | 1 |
| Jankowski, J | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Ran, JT | 2 |
| Zhou, YN | 2 |
| Tang, CW | 4 |
| Lu, JR | 1 |
| Wu, J | 1 |
| Lu, H | 2 |
| Yang, GD | 1 |
| Banning, A | 1 |
| Kipp, A | 1 |
| Schmitmeier, S | 1 |
| Löwinger, M | 1 |
| Florian, S | 1 |
| Krehl, S | 1 |
| Thalmann, S | 1 |
| Thierbach, R | 1 |
| Steinberg, P | 1 |
| Brigelius-Flohé, R | 1 |
| Mukherjee, P | 1 |
| Basu, GD | 1 |
| Tinder, TL | 1 |
| Subramani, DB | 1 |
| Bradley, JM | 1 |
| Arefayene, M | 1 |
| Skaar, T | 1 |
| De Petris, G | 1 |
| Ko, JC | 1 |
| Wang, LH | 1 |
| Jhan, JY | 1 |
| Ciou, SC | 1 |
| Hong, JH | 1 |
| Lin, ST | 1 |
| Lin, YW | 1 |
| Pino, MS | 1 |
| Milella, M | 2 |
| Gelibter, A | 2 |
| Sperduti, I | 1 |
| De Marco, S | 1 |
| Nuzzo, C | 1 |
| Bria, E | 2 |
| Carpanese, L | 1 |
| Ruggeri, EM | 2 |
| Carlini, P | 2 |
| Cognetti, F | 2 |
| Li, HH | 1 |
| Li, XW | 1 |
| Liu, H | 2 |
| Yang, Y | 2 |
| Xiao, J | 2 |
| Lv, Y | 2 |
| Yang, H | 2 |
| Zhao, L | 2 |
| Glück, S | 1 |
| Beales, IL | 1 |
| Ogunwobi, OO | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Rao, CV | 1 |
| Steele, VE | 1 |
| Swamy, MV | 1 |
| Patlolla, JM | 1 |
| Guruswamy, S | 1 |
| Kopelovich, L | 1 |
| Kuo, CH | 1 |
| Hu, HM | 1 |
| Tsai, PY | 1 |
| Wu, IC | 1 |
| Yang, SF | 1 |
| Chang, LL | 1 |
| Wang, JY | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Wu, DC | 1 |
| Wang, R | 1 |
| Ciren, YJ | 1 |
| Yang, JL | 1 |
| Zhang, B | 2 |
| Chen, JP | 1 |
| Futagami, S | 1 |
| Hamamoto, T | 1 |
| Shimpuku, M | 1 |
| Nagoya, H | 1 |
| Kawagoe, T | 1 |
| Horie, A | 1 |
| Shindo, T | 1 |
| Gudis, K | 1 |
| Sakamoto, C | 1 |
| Mathew, P | 1 |
| Yamakawa, N | 1 |
| Suemasu, S | 1 |
| Kimoto, A | 1 |
| Arai, Y | 1 |
| Ishihara, T | 1 |
| Yokomizo, K | 1 |
| Okamoto, Y | 1 |
| Otsuka, M | 1 |
| Tanaka, K | 1 |
| Mizushima, T | 1 |
| Mainetti, LE | 1 |
| Rozados, VR | 1 |
| Rossa, A | 1 |
| Bonfil, RD | 1 |
| Scharovsky, OG | 1 |
| Pierga, JY | 1 |
| Delaloge, S | 1 |
| Espié, M | 1 |
| Brain, E | 1 |
| Sigal-Zafrani, B | 1 |
| Mathieu, MC | 1 |
| Bertheau, P | 1 |
| Guinebretière, JM | 1 |
| Spielmann, M | 1 |
| Savignoni, A | 1 |
| Marty, M | 1 |
| Unger, KR | 1 |
| Romney, DA | 1 |
| Koc, M | 1 |
| Moskaluk, CA | 1 |
| Friel, CM | 1 |
| Foley, EF | 1 |
| Rich, TA | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Wang, J | 1 |
| Gao, PP | 1 |
| Altorki, NK | 1 |
| Christos, P | 1 |
| Port, JL | 1 |
| Lee, PC | 1 |
| Mirza, F | 1 |
| Spinelli, C | 1 |
| Keresztes, R | 1 |
| Beneck, D | 1 |
| Paul, S | 1 |
| Stiles, BM | 1 |
| Zhang, Y | 1 |
| Schrump, DS | 1 |
| Sagiv, E | 1 |
| Sheffer, M | 1 |
| Kazanov, D | 2 |
| Shapira, S | 1 |
| Naumov, I | 1 |
| Kraus, S | 1 |
| Domany, E | 1 |
| Arber, N | 2 |
| Zhang, RX | 1 |
| Wu, XJ | 1 |
| Wan, DS | 1 |
| Lu, ZH | 1 |
| Kong, LH | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Edelman, MJ | 1 |
| Hodgson, L | 1 |
| Wang, X | 1 |
| Christenson, R | 1 |
| Jewell, S | 1 |
| Vokes, E | 1 |
| Kratzke, R | 1 |
| Ding, X | 1 |
| Zhu, C | 1 |
| Qiang, H | 1 |
| Zhou, X | 1 |
| Zhou, G | 1 |
| Härdtner, C | 1 |
| Multhoff, G | 1 |
| Falk, W | 1 |
| Radons, J | 1 |
| Zhang, T | 1 |
| Su, LW | 1 |
| Zhu, YF | 1 |
| Lang, HJ | 1 |
| Zhang, F | 1 |
| Zhou, YA | 1 |
| Liang, XH | 1 |
| Wang, YJ | 2 |
| Marschner, N | 1 |
| Zaiss, M | 1 |
| Kim, YM | 1 |
| Pyo, H | 1 |
| Wenger, FA | 1 |
| Kilian, M | 1 |
| Achucarro, P | 1 |
| Heinicken, D | 1 |
| Schimke, I | 1 |
| Guski, H | 1 |
| Jacobi, CA | 1 |
| Müller, JM | 1 |
| Crane, CH | 1 |
| Mason, K | 1 |
| Janjan, NA | 1 |
| Milas, L | 1 |
| Ferrandina, G | 1 |
| Ranelletti, FO | 1 |
| Legge, F | 1 |
| Lauriola, L | 1 |
| Salutari, V | 1 |
| Gessi, M | 1 |
| Testa, AC | 1 |
| Werner, U | 1 |
| Navarra, P | 1 |
| Tringali, G | 1 |
| Battaglia, A | 1 |
| Scambia, G | 1 |
| Diperna, CA | 1 |
| Bart, RD | 4 |
| Sievers, EM | 2 |
| Ma, Y | 1 |
| Starnes, VA | 4 |
| Bremner, RM | 4 |
| Cerchietti, LC | 1 |
| Navigante, AH | 1 |
| Peluffo, GD | 1 |
| Diament, MJ | 1 |
| Stillitani, I | 1 |
| Klein, SA | 1 |
| Cabalar, ME | 1 |
| Wei, D | 1 |
| Wang, L | 2 |
| He, Y | 2 |
| Xiong, HQ | 1 |
| Abbruzzese, JL | 1 |
| Xie, K | 1 |
| Heath, EI | 1 |
| DeWeese, TL | 1 |
| Partin, AW | 1 |
| De Marzo, AM | 1 |
| Groopman, JD | 1 |
| Nelson, WG | 1 |
| Piantadosi, SA | 1 |
| Lieberman, R | 1 |
| Carducci, MA | 1 |
| Hada, M | 1 |
| Gupta, S | 1 |
| Adhami, VM | 1 |
| Subbarayan, M | 1 |
| MacLennan, GT | 1 |
| Lewin, JS | 1 |
| Hafeli, UO | 1 |
| Fu, P | 1 |
| Mukhtar, H | 1 |
| Di Cosimo, S | 1 |
| Malaguti, P | 1 |
| Pellicciotta, M | 1 |
| Terzoli, E | 1 |
| Chen, X | 1 |
| Wu, N | 1 |
| Sood, S | 1 |
| Wang, P | 1 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Lin, Y | 3 |
| Shih, WC | 1 |
| Lubet, RA | 1 |
| Yang, CS | 1 |
| Raut, CP | 1 |
| Nawrocki, S | 1 |
| Lashinger, LM | 1 |
| Davis, DW | 1 |
| Khanbolooki, S | 1 |
| Xiong, H | 1 |
| Ellis, LM | 1 |
| McConkey, DJ | 1 |
| Narayanan, BA | 2 |
| Narayanan, NK | 2 |
| Pittman, B | 1 |
| Reddy, BS | 2 |
| Yu, J | 1 |
| Tang, BD | 1 |
| Leung, WK | 1 |
| To, KF | 1 |
| Bai, AH | 1 |
| Zeng, ZR | 1 |
| Ma, PK | 1 |
| Go, MY | 1 |
| Hu, PJ | 1 |
| Sung, JJ | 1 |
| Backhus, LM | 3 |
| Starnes, M | 1 |
| Castanos, R | 2 |
| El-Rayes, BF | 2 |
| Zalupski, MM | 2 |
| Shields, AF | 2 |
| Ferris, AM | 2 |
| Vaishampayan, U | 2 |
| Heilbrun, LK | 2 |
| Venkatramanamoorthy, R | 2 |
| Adsay, V | 1 |
| Philip, PA | 2 |
| Shaik, MS | 1 |
| Chatterjee, A | 1 |
| Jackson, T | 1 |
| Singh, M | 1 |
| Sonpavde, G | 1 |
| Hayes, TG | 1 |
| Miwa, K | 1 |
| Oyama, K | 1 |
| Fujimura, T | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Tiberio, GA | 1 |
| Nodari, F | 1 |
| Strina, C | 1 |
| Marini, G | 1 |
| Pttman, B | 1 |
| Petasis, NA | 1 |
| Uddin, J | 1 |
| Schönthal, AH | 1 |
| Tuynman, JB | 1 |
| Buskens, CJ | 1 |
| Kemper, K | 1 |
| ten Kate, FJ | 1 |
| Offerhaus, GJ | 1 |
| Richel, DJ | 1 |
| van Lanschot, JJ | 1 |
| Blanquicett, C | 1 |
| Saif, MW | 1 |
| Buchsbaum, DJ | 1 |
| Eloubeidi, M | 1 |
| Vickers, SM | 1 |
| Chhieng, DC | 1 |
| Carpenter, MD | 1 |
| Sellers, JC | 1 |
| Russo, S | 1 |
| Diasio, RB | 1 |
| Johnson, MR | 1 |
| Chen, S | 1 |
| Bartick, T | 1 |
| Lev-Ari, S | 1 |
| Zinger, H | 1 |
| Yona, D | 1 |
| Ben-Yosef, R | 1 |
| Starr, A | 1 |
| Figer, A | 1 |
| Konturek, PC | 1 |
| Rembiasz, K | 1 |
| Burnat, G | 1 |
| Konturek, SJ | 1 |
| Tusinela, M | 1 |
| Bielanski, W | 1 |
| Rehfeld, J | 1 |
| Karcz, D | 1 |
| Hahn, E | 1 |
| Sievers, E | 1 |
| Lin, GY | 1 |
| Haupt, S | 1 |
| Kleinstern, J | 1 |
| Haupt, Y | 1 |
| Rubinstein, A | 1 |
| Dawson, SJ | 1 |
| Michael, M | 1 |
| Biagi, J | 1 |
| Foo, KF | 1 |
| Jefford, M | 1 |
| Ngan, SY | 1 |
| Leong, T | 1 |
| Hui, A | 1 |
| Milner, AD | 1 |
| Thomas, RJ | 1 |
| Zalcberg, JR | 1 |
| Cho, SJ | 1 |
| Kim, N | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Manza, SG | 1 |
| Rusin, B | 1 |
| Anai, S | 1 |
| Tanaka, M | 1 |
| Shiverick, KT | 1 |
| Kim, W | 1 |
| Takada, S | 1 |
| Boehlein, S | 1 |
| Goodison, S | 1 |
| Mizokami, A | 1 |
| Rosser, CJ | 1 |
| Lim, YJ | 1 |
| Rhee, JC | 1 |
| Bae, YM | 1 |
| Chun, WJ | 1 |
| Gaffney, DK | 1 |
| Winter, K | 1 |
| Dicker, AP | 1 |
| Miller, B | 1 |
| Eifel, PJ | 1 |
| Ryu, J | 1 |
| Avizonis, V | 1 |
| Fromm, M | 1 |
| Small, W | 1 |
| Greven, K | 1 |
| Zhu, FS | 1 |
| Chen, XM | 1 |
| Zhang, X | 1 |
| Feng, JX | 1 |
| Vegeler, RC | 1 |
| Yip-Schneider, MT | 1 |
| Ralstin, M | 1 |
| Wu, H | 1 |
| Crooks, PA | 1 |
| Neelakantan, S | 1 |
| Nakshatri, H | 1 |
| Sweeney, CJ | 1 |
| Schmidt, CM | 1 |
| Carles, J | 1 |
| Font, A | 1 |
| Mellado, B | 1 |
| Domenech, M | 1 |
| Gallardo, E | 1 |
| González-Larriba, JL | 1 |
| Catalan, G | 1 |
| Alfaro, J | 1 |
| Gonzalez Del Alba, A | 1 |
| Nogué, M | 1 |
| Lianes, P | 1 |
| Tello, JM | 1 |
| Huang, MT | 1 |
| Chen, ZX | 1 |
| Wei, B | 1 |
| Wang, CH | 1 |
| Huang, MH | 1 |
| Liu, R | 1 |
| Jakobsen, A | 1 |
| Mortensen, JP | 1 |
| Bisgaard, C | 1 |
| Lindebjerg, J | 1 |
| Rafaelsen, SR | 1 |
| Bendtsen, VO | 1 |
| Köhne, CH | 1 |
| De Greve, J | 1 |
| Hartmann, JT | 1 |
| Lang, I | 1 |
| Vergauwe, P | 1 |
| Becker, K | 1 |
| Braumann, D | 1 |
| Joosens, E | 1 |
| Müller, L | 1 |
| Janssens, J | 1 |
| Bokemeyer, C | 1 |
| Reimer, P | 1 |
| Link, H | 1 |
| Späth-Schwalbe, E | 1 |
| Wilke, HJ | 1 |
| Bleiberg, H | 1 |
| Van Den Brande, J | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Van Cutsem, E | 1 |
| de Heer, P | 1 |
| Sandel, MH | 1 |
| Guertens, G | 1 |
| de Boeck, G | 1 |
| Koudijs, MM | 1 |
| Nagelkerke, JF | 1 |
| Junggeburt, JM | 1 |
| de Bruijn, EA | 1 |
| van de Velde, CJ | 1 |
| Kuppen, PJ | 1 |
| Lönnroth, C | 1 |
| Andersson, M | 1 |
| Arvidsson, A | 1 |
| Nordgren, S | 1 |
| Brevinge, H | 1 |
| Lagerstedt, K | 1 |
| Lundholm, K | 1 |
| Agarwala, A | 1 |
| Fisher, W | 1 |
| Bruetman, D | 1 |
| McClean, J | 1 |
| Taber, D | 1 |
| Titzer, M | 1 |
| Juliar, B | 1 |
| Yu, M | 1 |
| Breen, T | 1 |
| Einhorn, LH | 1 |
| Hanna, N | 1 |
| Dragovich, T | 1 |
| Burris, H | 1 |
| Loehrer, P | 1 |
| Von Hoff, DD | 1 |
| Chow, S | 1 |
| Stratton, S | 1 |
| Green, S | 1 |
| Obregon, Y | 1 |
| Alvarez, I | 1 |
| Gordon, M | 1 |
| Chen, W | 1 |
| Bai, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for celecoxib and Adenocarcinoma
| Article | Year |
|---|---|
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protoc | 2003 |
28 trials available for celecoxib and Adenocarcinoma
| Article | Year |
|---|---|
Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; | 2017 |
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendiceal | 2013 |
Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemoradioth | 2014 |
Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.
Topics: Adenocarcinoma; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Fe | 2008 |
[Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fe | 2008 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
[Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].
Topics: Adenocarcinoma; Adult; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
[Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; | 2009 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; | 2011 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect | 2012 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arac | 2011 |
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens, Neoplasm; Apoptosis; Blood Vessels; Carcinoma, Sq | 2003 |
Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cachexi | 2004 |
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 2004 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Dis | 2007 |
Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apop | 2007 |
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiovascular | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Mo | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Relat | 2008 |
66 other studies available for celecoxib and Adenocarcinoma
| Article | Year |
|---|---|
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Topics: Adenocarcinoma; Aminopyridines; Animals; Antibodies, Monoclonal; Benzamides; Celecoxib; Cell Line, T | 2022 |
The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Wes | 2017 |
Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Estrogen Receptor alph | 2018 |
IL-1β-Mediated Up-Regulation of WT1D via miR-144-3p and Their Synergistic Effect with NF-κB/COX-2/HIF-1α Pathway on Cell Proliferation in LUAD.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Animals; Antagomirs; Celecoxib; Cel | 2018 |
Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Apoptosis; Carcinosarcoma; Celecoxib; Cel | 2018 |
Premetastatic soil and prevention of breast cancer brain metastasis.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Calgranulin B; CD11b Antigen | 2013 |
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
Topics: Adenocarcinoma; Administration, Metronomic; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antine | 2013 |
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Celecoxib; Cell Line, Tumor; | 2014 |
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxy | 2014 |
Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Celecoxib; Cycl | 2016 |
Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2016 |
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi | 2016 |
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line, Tumor | 2008 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Growth Processes; Cell Movement; Colonic Neoplasms; Cycloox | 2008 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclo | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small | 2009 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2009 |
Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endotheli | 2010 |
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
Topics: Adenocarcinoma; Animals; Apoptosis; Azoxymethane; Blotting, Western; Carcinogens; Celecoxib; Cell Pr | 2009 |
Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Celecoxib; Cell Proliferation; Cyclooxygenase 2; C | 2009 |
Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils.
Topics: AC133 Antigen; Adenocarcinoma; Animals; Antigens, CD; Blotting, Western; Celecoxib; Cell Count; Cell | 2010 |
Inflammatory pathogenesis of prostate cancer and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Celecoxib; Chemotherapy, Adjuvant; Cycloox | 2010 |
Low direct cytotoxicity of loxoprofen on gastric mucosal cells.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2010 |
Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide | 2011 |
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2011 |
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.
Topics: Adenocarcinoma; Celecoxib; Cell Cycle; Cell Transformation, Neoplastic; Colonic Polyps; Colorectal N | 2011 |
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Topics: Adenocarcinoma; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygen | 2011 |
(-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Camellia sinensis; Caspases; Catechin; Celecoxib; Cell Line | 2012 |
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone | 2012 |
Different cell cycle modulation by celecoxib at different concentrations.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Cyclooxygen | 2013 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Inc | 2002 |
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase Inhibitors; Electrophoretic Mobility Shift Assay; | 2004 |
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Doub | 2002 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; | 2004 |
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Celecoxib; Cell Division; Cyclo | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygena | 2004 |
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cele | 2004 |
Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
Topics: Adenocarcinoma; Animals; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2005 |
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Topics: Adenocarcinoma; Animals; Celecoxib; Cells, Cultured; Cyclooxygenase Inhibitors; Disease Models, Anim | 2005 |
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibi | 2006 |
PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Topics: Adenocarcinoma; Bone Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Humans; Male; Middle Aged; Pro | 2005 |
[A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 | 2005 |
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Growth Processes; Cyclooxygen | 2006 |
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lung N | 2005 |
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inh | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2005 |
Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Bird Diseases; Celecoxib; Cockatoos; Cyclooxygenas | 2006 |
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cell Line, Tumor; Ce | 2005 |
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Topics: Adenocarcinoma; Aged; Apoptosis Regulatory Proteins; Base Sequence; Biomarkers, Tumor; Biopsy, Needl | 2006 |
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Blotting, Western; Celecoxib; Cell Adhesion; Cyclooxygenase 2 Inhibitors; D | 2006 |
Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Ce | 2006 |
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Din | 2007 |
Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Blotting, Western; Cardiovascular Diseases; Celecoxib; Cell Line, Tumor; Cell Surviv | 2007 |
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; | 2007 |
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.
Topics: Adenocarcinoma; Animals; Carcinogens; Celecoxib; Cricetinae; Cyclooxygenase 2; Cyclooxygenase Inhibi | 2007 |
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colo | 2008 |
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Colonic Ne | 2008 |